Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

Introduction. The combination of BRAF and MEK inhibitors has deeply changed the treatment of BRAF V600-mutant non-small cell lung cancer patients. These agents demonstrated high antitumor activity as well as safe and manageable toxicity profile. Hypertension, pyrexia and increased liver enzymes are...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelsomino, Francesco, Di Federico, Alessandro, Tardio, Maria Lucia, Grilli, Giada, D’Errico, Antonietta, Ardizzoni, Andrea, Salvagni, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763820/
https://www.ncbi.nlm.nih.gov/pubmed/34436699
http://dx.doi.org/10.1007/s10637-021-01166-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763820/
https://www.ncbi.nlm.nih.gov/pubmed/34436699
http://dx.doi.org/10.1007/s10637-021-01166-7

Ejemplares similares